NCT00045526View on ClinicalTrials.gov

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

February 28, 2007

Conditions
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionRecurrent Esophageal CancerSquamous Cell Carcinoma of the EsophagusStage III Esophageal CancerStage IV Esophageal Cancer
Interventions
DRUG

erlotinib hydrochloride

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00045526 - Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer | Biotech Hunter | Biotech Hunter